secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0000950170-23-029955
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta NKX101 achieves 67% CR/CRi in AML Phase 1 with modified lymphodepletion
------------------------------------------------------------------------------

- In Flu/Ara-C cohort (n=6), NKX101 showed 67% CR/CRi rate (4/6) and 50% CR rate (3/6); 2 CRs MRD-negative.
- In Flu/Cy highest-dose cohort (n=18), CR/CRi rate was 22% (4/18) and CR rate 17% (3/18).
- NKX101 well tolerated; no dose-limiting toxicities, limited CRS/ICANS/GvHD across all doses.
- Expansion cohort with Flu/Ara-C to enroll 12-20 more patients; clinical update expected 1H 2024.
- Patients heavily pre-treated (median 2 prior lines, 90%+ prior venetoclax); majority poor-risk disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023029955/0000950170-23-029955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023029955/nktx-20230627.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer